{"filing":{"accession_number":"0001104659-26-076809","cik":"0001526119","ticker":"VSTM","company_name":"Verastem, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"tm2618546d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_8k.htm"},"events":[{"id":13137,"run_id":11660,"accession_number":"0001104659-26-076809","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.82,"summary":"Verastem disclosed preliminary clinical trial data from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375, a KRAS G12D inhibitor, demonstrating clinical efficacy and favorable safety profile across multiple cancer indications (pancreatic, colorectal, lung), and announced intent to collaborate with Erasca, Inc. on a preclinical combination study. This material clinical development milestone supports advancement toward Phase 2 trials and planned Phase 3 initiation by 1H 2027, materially affecting investor assessment of the company's pipeline and competitive position.","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10199,"accession_number":"0001104659-26-076809","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Verastem disclosed preliminary clinical trial data from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375, a KRAS G12D inhibitor, via a presentation posted to its website for an investor conference call on June 23, 2026. The presentation details clinical efficacy, safety profile, and development strategy across multiple cancer indications (pancreatic, colorectal, lung). This is a material operational/clinical milestone disclosure—the company is advancing a lead investigational asset through Phase 1/2 with demonstrated anti-tumor activity and favorable tolerability, supporting multiple Phase 2 trials and planned Phase 3 initiation by 1H 2027. While not a specific named event type (not M\u0026A, not a restatement, not a workforce action), it is clearly a material clinical development update that would affect investor assessment of the company's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:04:32.616783+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10200,"accession_number":"0001104659-26-076809","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Verastem disclosed preliminary clinical trial data from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375 in KRAS G12D-mutated solid tumors, along with an announcement of intent to collaborate with Erasca, Inc. on a preclinical combination study. This is a material operational/clinical development milestone for a biotech company—the disclosure of positive efficacy and safety data from a Phase 1/2 trial, combined with a new strategic collaboration, would affect a reasonable investor's assessment of the company's pipeline progress and competitive positioning. While not a traditional earnings release, M\u0026A activity, or governance event, this clinical update and partnership announcement represent material operational developments in the company's drug development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:04:32.616783+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10199,"accession_number":"0001104659-26-076809","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Verastem disclosed preliminary clinical trial data from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375, a KRAS G12D inhibitor, via a presentation posted to its website for an investor conference call on June 23, 2026. The presentation details clinical efficacy, safety profile, and development strategy across multiple cancer indications (pancreatic, colorectal, lung). This is a material operational/clinical milestone disclosure—the company is advancing a lead investigational asset through Phase 1/2 with demonstrated anti-tumor activity and favorable tolerability, supporting multiple Phase 2 trials and planned Phase 3 initiation by 1H 2027. While not a specific named event type (not M\u0026A, not a restatement, not a workforce action), it is clearly a material clinical development update that would affect investor assessment of the company's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:04:32.616783+00:00","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-06-23"},{"id":10200,"accession_number":"0001104659-26-076809","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Verastem disclosed preliminary clinical trial data from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375 in KRAS G12D-mutated solid tumors, along with an announcement of intent to collaborate with Erasca, Inc. on a preclinical combination study. This is a material operational/clinical development milestone for a biotech company—the disclosure of positive efficacy and safety data from a Phase 1/2 trial, combined with a new strategic collaboration, would affect a reasonable investor's assessment of the company's pipeline progress and competitive positioning. While not a traditional earnings release, M\u0026A activity, or governance event, this clinical update and partnership announcement represent material operational developments in the company's drug development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:04:32.616783+00:00","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-06-23"}]}